Non-animal testing is key to next phase of pharma growth
India’s pharmaceutical sector is being urged to expand non-animal testing models to improve drug-development efficiency, increase human relevance in safety assessment, and reduce dependence on laboratory animals.
- Conventional animal tests do not always predict human outcomes, creating a gap between preclinical testing and clinical success.
- Non-animal testing can improve efficiency, competitiveness, and regulatory science if validated methods are accepted more widely.
What happened
India’s pharmaceutical sector is being urged to accelerate the use of non-animal testing models in drug development. Animal tests often fail to predict how compounds behave in humans, which contributes to high attrition in development and slows the path from discovery to approved treatment.
Why the issue matters
UPSC can frame this topic around the need for human-relevant alternatives in drug discovery, the regulatory acceptance of non-animal data, and the balance between innovation, safety, and ethical reduction of animal use. The issue also links to biotechnology policy, laboratory standards, and the competitiveness of India’s pharmaceutical industry.
Related dispatches
